Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment
Optic neuritis is an inflammatory optic neuropathy that is commonly indicative of autoimmune
neurological disorders including multiple sclerosis, myelin-oligodendrocyte glycoprotein …
neurological disorders including multiple sclerosis, myelin-oligodendrocyte glycoprotein …
Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice
EC Contentti, JI Rojas, E Cristiano, VD Marques… - Multiple sclerosis and …, 2020 - Elsevier
Background During the last two decades, neuromyelitis optica spectrum disorder (NMOSD)
has undergone important changes, with new diagnostic markers and criteria, better …
has undergone important changes, with new diagnostic markers and criteria, better …
Rapid immunodot AQP4 assay for neuromyelitis optica spectrum disorder
Y Fu, J Bi, Y Yan, X Sun, K Li, SY Kim, SM Han… - JAMA …, 2023 - jamanetwork.com
Importance Immunoglobulin G autoantibodies for aquaporin 4 (AQP4-IgG) serve as
diagnostic biomarkers for neuromyelitis optica spectrum disorder (NMOSD), and the most …
diagnostic biomarkers for neuromyelitis optica spectrum disorder (NMOSD), and the most …
International delphi consensus on the management of AQP4-IgG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab
F Paul, R Marignier, J Palace, G Arrambide… - Neurology …, 2023 - AAN Enterprises
Background and Objectives Neuromyelitis optica spectrum disorder (NMOSD) is a rare
debilitating autoimmune disease of the CNS. Three monoclonal antibodies were recently …
debilitating autoimmune disease of the CNS. Three monoclonal antibodies were recently …
Pediatric NMOSD: a review and position statement on approach to work-up and diagnosis
S Tenembaum, EA Yeh… - Frontiers in …, 2020 - frontiersin.org
Neuromyelitis Optica Spectrum Disorder (NMOSD) is an inflammatory demyelinating
disease of the central nervous system (CNS) primarily affecting the optic nerves and spinal …
disease of the central nervous system (CNS) primarily affecting the optic nerves and spinal …
Serum and cerebrospinal fluid biomarkers in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disease
A Dinoto, E Sechi, EP Flanagan, S Ferrari… - Frontiers in …, 2022 - frontiersin.org
The term neuromyelitis optica spectrum disorder (NMOSD) describes a group of clinical-MRI
syndromes characterized by longitudinally extensive transverse myelitis, optic neuritis …
syndromes characterized by longitudinally extensive transverse myelitis, optic neuritis …
Neuromyelitis optica spectrum disorders
S Paul, GP Mondal, R Bhattacharyya, KC Ghosh… - Journal of the …, 2021 - Elsevier
The disease concept of Neuromyelitis Optica Spectrum Disorders (NMOSD) has undergone
a significant change over the last two decades including the detection of Myelin …
a significant change over the last two decades including the detection of Myelin …
Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG-and MOG-IgG-associated diseases
S Mader, T Kümpfel, E Meinl - Current Opinion in Neurology, 2020 - journals.lww.com
Current Opinion in Neurology Log in or Register Subscribe to journalSubscribe Get new
issue alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation …
issue alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation …
[HTML][HTML] Monoclonal antibody therapies beyond complement for NMOSD and MOGAD
V Redenbaugh, EP Flanagan - Neurotherapeutics, 2022 - Elsevier
Abstract Aquaporin-4 (AQP4)-IgG seropositive neuromyelitis optica spectrum disorders
(AQP4-IgG seropositive NMOSD) and myelin oligodendrocyte glycoprotein (MOG)–IgG …
(AQP4-IgG seropositive NMOSD) and myelin oligodendrocyte glycoprotein (MOG)–IgG …
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder
R Marignier, SJ Pittock, F Paul, HJ Kim… - Multiple Sclerosis and …, 2022 - Elsevier
Abstract Background The N-MOmentum trial, a double-blind, randomized, placebo-
controlled, phase 2/3 study of inebilizumab in neuromyelitis optica spectrum disorder …
controlled, phase 2/3 study of inebilizumab in neuromyelitis optica spectrum disorder …